itive Breast Cancer HR-Positive Breast CancerHR-Positive Breast CancerHarold J. Burstein
参考文献: [1] The Natural History of Hormone Receptor-Positive Breast Cancer. Oncology 2012, 26, 688–694, 696. [2] Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- ...
Lead neoMONARCH Researcher Provides Insight on Abemaciclib Potential in HR-Positive Breast...Gina Columbus
Optimal therapy in breast cancer HR-positive and Her-2 negative Oncolog-HematologGrecea, Dana
[18]Li TF, Shan Z, Lin Y, et al. Sequential versus concurrent use of chemotherapy and endocrinetherapy in the adjuvant treatment of ER-positive breast cancer: A systematicreview and Bayesian network meta-analysis. 2019 ...
The DESTINY-Breast06 trial investigated earlier and broader use of trastuzumab deruxtecan in patients with metastatic hormone-receptor-positive breast cancer, and demonstrated improvements in progression-free survival over standard chemotherapy. These data provide a meaningful advance; however, this strategy...
[8] Turner NC, et al.Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer:results from the Phase III CAPItello-291 trial.2022 SABCS.GS3-04. ...
[4]Stephen Chia, et al.Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.Journal of Clinical Oncology 41, no. 16_suppl (June 01,...
[1] The Natural History of Hormone Receptor-Positive Breast Cancer. Oncology 2012, 26, 688–694, 696. [2] Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A ...
(T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06...